Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to examine if paricalcitol may reduce progression of
graft fibrosis and proteinuria in kidney transplant patients. Cyclosporine and tacrolimus
have a detrimental long-term effect by inducing graft fibrosis. About 50% of graft losses are
related to interstitial fibrosis. Paricalcitol is a vitamin D receptor activator indicated
for treatment of secondary hyperparathyroidism. Paricalcitol is known to exert an
anti-inflammatory and antifibrotic and attenuate cyclosporine-induced fibrosis. Paricalcitol
is also shown to be renoprotective by reducing proteinuria. No randomized controlled trials
with paricalcitol are performed in renal transplant patients examining the effect on
proteinuria and graft fibrosis.